How good are we at predicting the fate of someone with acute myeloid leukaemia?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed.

1. Mutational Signatures and Machine Learning for Risk Stratification of Acute Myeloid Leukaemia Based on Targeted Sequencing Data.Cancers · 2026
   Article
2. Effective and Successful Quantification of Leukemia-Specific Immune Cells in AML Patients' Blood or Culture, Focusing on Intracellular Cytokine and Degranulation Assays.International journal of molecular sciences · 2024
   Article
3. Measurable residual disease (MRD)-testing in haematological and solid cancers.Leukemia · 2024
   Review
4. CSRP2 transcript levels after consolidation therapy increase prognostic prediction ability in B-cell acute lymphoblastic leukaemia.Biomolecules & biomedicine · 2023
   Article
5. Have we been qualifying measurable residual disease correctly?Leukemia · 2023
   Review
6. Allogeneic transplantation in acute myelogenous leukemia: a comprehensive single institution's experience.Haematologica · 2023
   Article
7. The use of prognostic models in allogeneic transplants: a perspective guide for clinicians and investigators.Blood · 2023
   Article
8. Allogeneic transplantation for advanced acute leukemia.Hematology. American Society of Hematology. Education Program · 2022
   Article
9. HERVs characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy.American journal of hematology · 2022
   Article
10. Improving prediction accuracy in acute myeloid leukaemia: micro-environment, immune and metabolic models.Leukemia · 2021
    Article
11. Targeted Therapies for the Evolving Molecular Landscape of Acute Myeloid Leukemia.Cancers · 2021
    Review
12. Being certain even when you're wrong: heuristics and thin slicing in haematopoietic cell transplantation.Bone marrow transplantation · 2021
    Article
13. New treatments for acute myeloid leukemia: how much has changed?Leukemia · 2021
    Article
14. Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation.Bone marrow transplantation · 2020
    Article
15. External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation.Blood advances · 2019
    Article
16. New study-designs to address the clinical complexity of acute myeloid leukemia.Leukemia · 2019
    Article
17. Cytotoxic therapy in acute myeloid leukemia: not quite dead yet.Hematology. American Society of Hematology. Education Program · 2018
    Review
18. New drugs in AML: uses and abuses.Leukemia · 2018
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as